Navigation Links
Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
Date:7/22/2014

BETHLEHEM, Pa., July 22, 2014 /PRNewswire/ -- Eyeon Therapeutics has received a Notice of Allowance on a novel dry eye treatment based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO.  The product has been shown to be safe and effective in a small trial previously published.  Mark Mitchnick, MD, CEO states, "This first set of claims around the polymer and its class will go a long way to moving this technology into the commercial phase.  We have been using it in several development projects, and we believe it has promise in many ocular formulations as well as in other areas.  Helping Eyeon gain a proprietary position in this very important market is a great example of what Particle Sciences offers its partners." 

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few therapies.  Our product offers a unique approach that is clinically validated and useful in a number of ocular applications.  In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons." 

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at dave@eyeontherapeutics.com

Contact:
Maureen Grieco
610-861-4701
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Measuring Systems® Celebrates 40 Years of Leadership
2. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
3. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
4. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
5. Varian Medical Systems Signs Purchase Agreement with Advanced Particle Therapy LLC to Supply Technology for the Georgia Proton Treatment Center to be operated by Emory Healthcare
6. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
7. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Waters Introduces CORTECS Columns Featuring Solid-Core Particle Technology
10. HORIBA Scientific Launches New Raman ParticleFinder Software
11. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen ... services to communities in the greater Birmingham area, is joining the Chris Hammond ... young people in the region. , The Chris Hammond Youth Foundation maintains athletic ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... Fresh Wave® ... Liquid eco-friendly odor-control solution for colleges and universities at the APPA 2017 ... effectively eliminate severe cannabis and tobacco smoke odors without the use of harsh chemicals, ...
(Date:7/21/2017)... ... 2017 , ... Hospital M&A activity slowed in the second quarter of 2017, ... rose to 23 in the second quarter, up 15% from the 20 publicly announced ... deals in the year-ago second quarter. Only four of the transactions disclosed a purchase ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
Breaking Medicine News(10 mins):